Impact of therapeutic plasmapheresis on the duration of organ failure in patients with hypertriglyceridemia-associated acute pancreatitis

• DOI: 10.1186/s13613-024-01285-3
• Publication Date: 2024-04-15T10:02:09Z
• Authors: Lanting Wang; Jing Zhou; Cheng Lv; Donghuang Hong; Zuozheng Wang; Wenjian Mao; Yuxiu Liu; Zixiong Zhang; Yuanzhen Li; Gang Li; Bo Ye; Baiqiang Li; Longxiang Cao; Zhihui Tong; Weiqin Li; Lu Ke; ; Qi Yang; Jiajia Lin; Lin Gao; Yan Chen; Nonghua Lv; Yin Zhu; Liang Xia; Wenhua He; Zhenping Chen; Xinting Pan; Qingyun Zhu; Youdong Wan; Hong Mei; Kang Li; Miao Chen; Chengjian He; Hongyi Yao; Zigui Zhu; Weili Lu; Weihua Gu; Feng Zhou; Shumin Tu; Long Fu; Bing Xue; Haibin Ni; Xiaofei Huang; Dandan Zhou; Guoxiu Zhang; Lening Ren; Dahuan Li; Xiangyang Zhao; Wei Zhao; Xiaomei Chen; Junli Sun; Keke Xin; Weiwei Chen; Qingcheng Xu; Jingchun Song; Qingbo Zeng; Min Shao; Dongsheng Zhao; Jianfeng Tu; Hongguo Yang; Bin Wu; Huaguang Ye; Mingzhi Chen; Mei Yang; Hong Gao; Qiang Li; Lijuan Zhao; Guobing Chen; Yafei Li; Honghai Xia; Dongliang Yang; Shusheng Zhou; Siyao Liu; Jiyan Lin; Songjing Shi; Weijie Yao; Shan Xu; Lei Yu; Feng Guo; Yongjun Lin; Yun Zhou; Yue Long; Guixian Luo; Quanxing Feng; Zhiyong Liu
• Keywords: Plasmapheresis

Abstract Background Plasmapheresis is widely used for severe hypertriglyceridemia-associated acute pancreatitis (HTG-AP) to remove excessive triglycerides from plasma. This study aimed evaluate whether plasmapheresis could improve the duration of organ failure in HTG-AP patients. Methods We analyzed a cohort patients multicenter, prospective, long-running registry (the PERFORM) collecting admitted sites within 72 h onset symptoms. was based on data collected November 2020 March 2023. Patients who had at enrollment were involved analyses. The primary outcome time resolution 14 days. Multivariable Cox regression model association between and resolution. Directed acyclic graph (DAG) identify potential confounders. Results A total 122 included (median [IQR] sequential assessment (SOFA) score enrollment, 3.00 [2.00–4.00]). Among patients, 46 underwent plasmapheresis, 76 received medical treatment. DAG revealed that baseline serum triglyceride, APACHE II score, respiratory failure, cardiovascular renal After adjusting selected confounders, there no significant difference undergoing those receiving exclusive treatment (HR = 1.07; 95%CI 0.68–1.68; P 0.777). Moreover, use associated with higher ICU requirements (97.8% [45/46] vs. 65.8% [50/76]; OR, 19.33; 2.20 169.81; 0.008). Conclusions In early not accelerated compared but may be more admissions. Trial registration : PERFORM registered Chinese Clinical Registry (ChiCTR2000039541). Registered 30 October 2020.